Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>

Vogel, Victor G.·2006·JAMA

Abstract

CONTEXT: Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis. OBJECTIVE: To compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast cancer and other disease outcomes. DESIGN, SETTING, AND PATIENTS: The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial, a prospective, double-blind, randomized clinical trial conducted beginning July 1, 1999, in nearly 200 clinical centers throughout North America, with final analysis initiated after at least 327 incident invasive breast cancers were diagnosed. Patients were 19,747 postmenopausal women of mean age 58.5 years with increased 5-year breast cancer risk (mean risk, 4.03% [SD, 2.17%]). Data reported are based on a cutoff date of December 31, 2005. INTERVENTION: Oral tamoxifen (20 mg/d) or raloxifene (60 mg/d) over 5 years. MAIN OUTCOME MEASURES: Incidence of invasive breast cancer, uterine cancer, noninvasive breast cancer, bone fractures, thromboembolic events. RESULTS: There were 163 cases of invasive breast cancer in women assigned to tamoxifen and 168 in those assigned to raloxifene (incidence, 4.30 per 1000 vs 4.41 per 1000; risk ratio [RR], 1.02; 95% confidence interval [CI], 0.82-1.28). There were fewer cases of noninvasive breast cancer in the tamoxifen group (57 cases) than in the raloxifene group (80 cases) (incidence, 1.51 vs 2.11 per 1000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 with raloxifene (RR, 0.62; 95% CI, 0.35-1.08). No differences were found for other invasive cancer sites, for ischemic heart disease events, or for stroke. Thromboembolic events occurred less often in the raloxifene group (RR, 0.70; 95% CI, 0.54-0.91). The number of osteoporotic fractures in the groups was similar. There were fewer cataracts (RR, 0.79; 95% CI, 0.68-0.92) and cataract surgeries (RR, 0.82; 95% CI, 0.68-0.99) in the women taking raloxifene. There was no difference in the total number of deaths (101 vs 96 for tamoxifen vs raloxifene) or in causes of death. CONCLUSIONS: Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. The risk of other cancers, fractures, ischemic heart disease, and stroke is similar for both drugs. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00003906.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.295.23.joc60074

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 1,652

Metadata

Authors
Vogel, V. G.
Affiliations
University of Pittsburgh (US)
Corresponding author
Vogel, Victor G.
Venue
JAMA
Published
2006-06-21
Volume
295
Issue
23
Pages
2727
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2107859602
Cited by
1,652
References
50
Citations by year
2026: 14 · 2025: 28 · 2024: 35 · 2023: 25 · 2022: 38 · 2021: 37 · 2020: 53 · 2019: 55 · 2018: 48 · 2017: 69 · 2016: 63 · 2015: 95 · 2014: 87 · 2013: 111 · 2012: 98
FWCI
97.69
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (U10CA069651, U10CA037377, U10CA069974, U10CA012027)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
tamoxifen, raloxifene, breast cancer chemoprevention, invasive breast cancer, non-invasive breast cancer, uterine cancer, bone fractures, thromboembolic events, postmenopausal women, drug safety, selective estrogen receptor modulators, breast cancer risk reduction
MeSH terms
Adult, Aged, Breast Neoplasms, Cataract, Cause of Death, Double-Blind Method, Female, Humans, Middle Aged, Risk, Tamoxifen, Thrombosis, Uterine Neoplasms, Incidence, Myocardial Ischemia, Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. https://app.cochat.ai/papers/10.1001/jama.295.23.joc60074
The paper
Vogel, V. G. (2006). Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. JAMA. https://doi.org/10.1001/jama.295.23.joc60074

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.